Results for tag: "Breo"

The Breo market is a segment of the respiratory drug market that focuses on the treatment of chronic obstructive pulmonary disease (COPD). Breo is a combination of two drugs, fluticasone furoate and vilanterol, which work together to reduce inflammation and open up the airways. Breo is used to treat the symptoms of COPD, such as shortness of breath, wheezing, and coughing. Breo is also used to reduce the risk of COPD exacerbations, which are episodes of worsening symptoms. The Breo market is a growing segment of the respiratory drug market, with a number of companies developing and marketing products. Companies such as GlaxoSmithKline, AstraZeneca, and Novartis are all involved in the development and marketing of Breo products. Other companies, such as Mylan and Teva Pharmaceuticals, are also involved in the production and distribution of Breo products. Show Less Read more